Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qizhitongluo Capsule is a traditional Chinese medicine (TCM) compound developed by the China Academy of Chinese Medical Sciences for the treatment of ischemic stroke. It is specifically formulated for patients in the recovery phase who exhibit the TCM syndrome of Qi deficiency and blood stasis. The capsule is designed to replenish Qi and activate blood circulation, addressing the physiological blockages associated with post-stroke recovery. Clinical evaluation includes a multicenter, randomized, double-blind Phase 4 trial (NCT01762163) comparing its efficacy and safety against placebo and Naoxintong Capsule, with a focus on improving neurological outcomes and motor function, particularly in the lower limbs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qizhitongluo Capsule.